Low-Energy Extracorporeal Shock Wave Therapy to Treat Lesser Metatarsal Fracture Nonunion: Case Report

2012 ◽  
Vol 33 (12) ◽  
pp. 1128-1132 ◽  
Author(s):  
Zacharia M. Silk ◽  
Raju S. Alhuwaila ◽  
James D. Calder
Keyword(s):  
Shock Wave ◽  
Case Report ◽  
Extracorporeal Shock Wave Therapy ◽  
Low Energy ◽  
Shock Wave Therapy ◽  
Extracorporeal Shock Wave ◽  
Metatarsal Fracture ◽  
Fracture Nonunion

scholarly journals Extracorporeal shock-wave therapy in the treatment of pseudoarthrosis: a case report

Cases Journal ◽  
2008 ◽  
Vol 1 (1) ◽  
Author(s):  
Stefan Endres ◽  
Markus Weiskirch ◽  
Christiane Hinz ◽  
Felix Hütter ◽  
Axel Wilke
Keyword(s):  
Shock Wave ◽  
Case Report ◽  
Extracorporeal Shock Wave Therapy ◽  
Shock Wave Therapy ◽  
Extracorporeal Shock Wave

scholarly journals Low-Energy Extracorporeal Shock Wave Therapy Ameliorates Kidney Function in Diabetic Nephropathy

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Chang-Chun Hsiao ◽  
Wei-Han Huang ◽  
Kuang-Hung Cheng ◽  
Chien-Te Lee
Keyword(s):  
Oxidative Stress ◽  
Shock Wave ◽  
Diabetic Nephropathy ◽  
Rat Model ◽  
Renal Fibrosis ◽  
Tissue Repair ◽  
Extracorporeal Shock Wave Therapy ◽  
Low Energy ◽  
Shock Wave Therapy ◽  
Extracorporeal Shock Wave

Background. Diabetic nephropathy is the most common cause of end-stage renal disease. Traditional therapy for diabetic nephropathy has focused on supportive treatment, and there is no significant effective therapy. We investigated the effect of low-energy extracorporeal shock wave therapy on a diabetic nephropathy rat model. Methods. Streptozotocin-induced diabetic nephropathy rats were treated with six sessions of low-energy extracorporeal shock wave therapy (weekly for six consecutive weeks) or left untreated. We assessed urinary creatinine and albumin, glomerular volume, renal fibrosis, podocyte number, renal inflammation, oxidative stress, and tissue repair markers (SDF-1 and VEGF) six weeks after the completion of treatment. Results. The six-week low-energy extracorporeal shock wave therapy regimen decreased urinary albumin excretion as well as reduced glomerular hypertrophy and renal fibrosis in the rat model of diabetic nephropathy. Moreover, low-energy extracorporeal shock wave therapy increased podocyte number in diabetic nephropathy rats. This was likely primarily attributed to the fact that low-energy extracorporeal shock wave therapy reduced renal inflammation and oxidative stress as well as increased tissue repair potency and cell proliferation. Conclusions. Low-energy extracorporeal shock wave therapy preserved kidney function in diabetic nephropathy. Low-energy extracorporeal shock wave therapy may serve as a novel noninvasive and effective treatment of diabetic nephropathy.

Low-Energy Extracorporeal Shock Wave Therapy as a Treatment for Greater Trochanteric Pain Syndrome

2009 ◽  
Vol 37 (9) ◽  
pp. 1806-1813 ◽  
Author(s):  
John P. Furia ◽  
Jan D. Rompe ◽  
Nicola Maffulli
Keyword(s):  
Shock Wave ◽  
Effective Treatment ◽  
Pain Syndrome ◽  
Extracorporeal Shock Wave Therapy ◽  
Low Energy ◽  
Visual Analog Score ◽  
Shock Wave Therapy ◽  
Greater Trochanteric Pain Syndrome ◽  
Extracorporeal Shock Wave ◽  
Chi Square Analysis

Background Greater trochanteric pain syndrome is often a manifestation of underlying gluteal tendinopathy. Extracorporeal shock wave therapy is effective in numerous types of tendinopathies. Hypothesis Shock wave therapy is an effective treatment for chronic greater trochanteric pain syndrome. Study Design Case control study; Level of evidence, 3. Methods Thirty-three patients with chronic greater trochanteric pain syndrome received low-energy shock wave therapy (2000 shocks; 4 bars of pressure, equal to 0.18 mJ/mm 2; total energy flux density, 360 mJ/mm2). Thirty-three patients with chronic greater trochanteric pain syndrome were not treated with shock wave therapy but received additional forms of nonoperative therapy (control). All shock wave therapy procedures were performed without anesthesia. Evaluation was by change in visual analog score, Harris hip score, and Roles and Maudsley score. Results Mean pretreatment visual analog scores for the control and shock wave therapy groups were 8.5 and 8.5, respectively. One, 3, and 12 months after treatment, the mean visual analog score for the control and shock wave therapy groups were 7.6 and 5.1 (P < .001), 7 and 3.7 (P < .001), and 6.3 and 2.7 (P < .001), respectively. One, 3, and 12 months after treatment, mean Harris hip scores for the control and shock wave therapy groups were 54.4 and 69.8 (P < .001), 56.9 and 74.8 (P < .001), and 57.6 and 79.9 (P < .001), respectively. At final follow-up, the number of excellent, good, fair, and poor results for the shock wave therapy and control groups were 10 and 0 (P < .001), 16 and 12 (P < .001), 4 and 13 (P < .001), and 3 and 8 (P < .001), respectively. Chi-square analysis showed the percentage of patients with excellent (1) or good (2) Roles and Maudsley scores (ie, successful results) 12 months after treatment was statistically greater in the shock wave therapy than in the control group (P < .001). Conclusion Shock wave therapy is an effective treatment for greater trochanteric pain syndrome.

Sign in / Sign up

Export Citation Format

Share Document